Please login to the form below

Not currently logged in
Email:
Password:

Orion

This page shows the latest Orion news and features for those working in and with pharma, biotech and healthcare.

Bayer’s Nubeqa receives MHRA approval to treat metastatic prostate cancer

Bayer’s Nubeqa receives MHRA approval to treat metastatic prostate cancer

Nubeqa, developed jointly by Bayer and Orion, is an oral androgen receptor inhibitor with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity,

Latest news

More from news
Approximately 3 fully matching, plus 36 partially matching documents found.

Latest Intelligence

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    75. Orion/ Bayer. Co-development, option to co-promote in Europe. OraQuick HCV rapid test in US.

  • Pharma deals during June 2014 Pharma deals during June 2014

    Financial terms were not disclosed but include milestone and royalties. Staying with the mid-caps and turning to prostate cancer, Bayer and Orion entered into a joint development deal for ... The companies will jointly fund the phase III trials. Orion

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Orion appoints VP of oncology, R&D Orion appoints VP of oncology, R&D

    He said: “My new position at Orion allows me to maintain and deepen my research focus, which is to develop such treatments for cancer patients wherever they live. ... I hope that my long background in the academia will help in the initiation of new

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....